Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2024-04-12
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of
cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer
(CRPC).